SCHEMBL6414671

SCHEMBL6414671

NN=C(c1ccccc1O)c1nc2nonc2nc1NCc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
RXFP1 Q9HBX9 1/20 0.37
KDM4E B2RXH2 3/20 0.36
MAPK1 P28482 3/20 0.36
MAPT P10636 2/20 0.36
HTT P42858 2/20 0.36
BLM P54132 2/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
IDO1 P14902 1/20 0.35
ACHE P22303 1/20 0.34
APP P05067 1/20 0.34
PLAU P00749 2/20 0.34
STAT6 P42226 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414661 1.00 MEN1 (0.37) MEN1KMT2ARXFP1KDM4EMAPK1
SCHEMBL6415718 0.89 EGFR (0.39) MEN1KMT2ARXFP1KDM4EMAPK1
SCHEMBL6415738 0.89 EGFR (0.39) MEN1KMT2ARXFP1KDM4EMAPK1
SCHEMBL6413677 0.88 KDM5B (0.42) MEN1KMT2AKDM4EMAPK1MAPT
SCHEMBL6413651 0.88 KDM5B (0.42) MEN1KMT2AKDM4EMAPK1MAPT
SCHEMBL6417119 0.88 TUBB (0.40) MEN1KMT2ARXFP1KDM4EMAPK1
SCHEMBL6433414 0.85 EGFR (0.39) MEN1KMT2AKDM4EMAPK1MAPT
SCHEMBL6416987 0.85 EGFR (0.39) MEN1KMT2AMAPK1LMNASMN1; SMN2
SCHEMBL6414138 0.84 STAT6 (0.38) MEN1KMT2ARXFP1KDM4EMAPK1
SCHEMBL6414153 0.84 STAT6 (0.38) MEN1KMT2ARXFP1KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MEN1 4392/4885KMT2A 3640/4885RXFP1 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.